drug
(mometasone furoate + olopatadine hydrochloride)
Marketedupdated 3mo agoby Hikma Pharmaceuticals USA Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (mometasone furoate + olopatadine hydrochloride)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 4, 2034
~8.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (16)
- Apr 8, 2039compositionUS 12303635
- Sep 3, 2038formulationUS 11679210
- Sep 4, 2034method-of-use (U-3297)US 10016443
- Sep 4, 2034formulationUS 10376526
- Sep 4, 2034formulationUS 10517880
- Sep 4, 2034method-of-use (U-3297)US 10548907
- Sep 4, 2034formulationUS 10561672
- Sep 4, 2034method-of-use (U-3297)US 10646500
- Sep 4, 2034method-of-use (U-3296)US 10758550
- Sep 4, 2034method-of-use (U-3295)US 10765686
- Sep 4, 2034method-of-use (U-3297)US 11400101
- Sep 4, 2034method-of-use (U-3297)US 12064442
- Sep 4, 2034formulationUS 9078923
- Sep 4, 2034formulationUS 9370483
- Sep 4, 2034formulationUS 9750754
- Sep 4, 2034formulationUS 9937189
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 46m ago
Found something off?
comments(0)
5-min edit window · permanent after that